iA Global Asset Management Inc. Sells 85,772 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

iA Global Asset Management Inc. lowered its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 19.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 355,119 shares of the company's stock after selling 85,772 shares during the period. iA Global Asset Management Inc.'s holdings in Teva Pharmaceutical Industries were worth $7,827,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Smithfield Trust Co boosted its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at about $50,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth approximately $66,000. IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after purchasing an additional 1,960 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $104,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 0.5 %

Shares of NYSE TEVA traded up $0.08 during midday trading on Monday, hitting $16.18. 8,023,829 shares of the company traded hands, compared to its average volume of 9,436,029. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The firm has a market cap of $18.34 billion, a P/E ratio of -11.16, a P/E/G ratio of 1.44 and a beta of 0.82. The stock has a 50-day moving average price of $17.70 and a 200 day moving average price of $18.19. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Remove Ads

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several recent analyst reports. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Bank of America lowered their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Finally, Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.